http://medconferencestoday.com

Breaking Medical Conference News...

Government Of Canada Supports Improvements To The Postgraduate Medical Education System

The Honourable Leona Aglukkaq, Minister of Health, announced federal funding of over $1.5 million to the Association of Faculties of Medicine of Canada (AFMC) to strengthen the postgraduate medical education system. The funding will help provide physicians in training with the necessary skills to meet the health care needs of Canadians...

HealthPartners And American Hospital Association Partner For National Launch Of Joining Forces

HealthPartners Institute for Medical Education and the American Hospital Association (AHA) have partnered with more than a dozen national organizations to launch an initiative designed to generate awareness among medical professionals and others within communities about the challenges -- medical, social and emotional -- that veterans and their families face as they return home from military service.

WHO Report Launched At Ministerial Conference Calls For Joint Action To Manage Migration Of Health Professionals

A WHO report highlights the need for governments and leaders in the WHO European Region to better manage health personnel issues, including migration, by improving data collection, developing effective policies and reducing migration's negative effects.

Anestvise Inc will Create New Jobs at New Manufacturing Facility in Eastern Europe

Anestvice Inc. www.anestvice.com , whose customers include major pharmaceutical industry players, specializes in manufacturing of medical devices. The company’s long-term plans call for it’s new facility to serve as a device manufacturing center, using advanced technology in ...
(613) 686-5745 Cerepotec Pharmalef

Medical Students Urge Speaker Pelosi To Keep Her Promise

The American Medical Student Association (AMSA) urges Speaker Nancy Pelosi to keep her promise and allow a vote on a single payer substitution amendment to the House health care reform bill, to be introduced by Representative Anthony Weiner [D-NY].

Medical Students Nationwide Remove Conflicts Of Interest - 5th Annual National PharmFree Week Underway, USA

Medical students across the country are celebrating the 5th Annual National PharmFree Week, "Promoting Evidence-Based Practice, Preserving Pharmaceutical Innovation," which allows them to educate themselves and their colleagues about reclaiming the ethics of medicine by removing conflicts of interest and restoring the patient-physician relationship.

WPIC Partners With Pitt And Community Members To Bring Unique Depression Counseling To Students

According to national statistics, one out of four college students will experience some form of depression by the age of 24, and nearly half of all college students report feeling so depressed at some point in time that they have trouble functioning.

Clinical Research Professionals are Still in Demand despite the World Economic Crisis

Despite the world economic crisis, the clinical research field is currently expanding faster than the introduction of newly qualified professionals that inevitably creates a demand. Most people are under the impression that the barriers to enter this industry are extremely difficult to ...
(613) 686-5745 Cerepotec Pharmalef

Medical Students Call For Comprehensive Sexuality Education Programs

The American Medical Student Association (AMSA), the nation's largest, independent medical student association, announces its support for the Responsible Education About Life (REAL) Act, which was introduced this week by Senator Frank Lautenberg (D-NJ) and Representative Barbara Lee (D-CA). This bill authorizes the first ever federal funding for comprehensive sexuality education.

University Of Queensland Ipswich Now Home To 155 Medical Students, Australia

While most students are still enjoying their break, UQ's medical students are starting classes this week. 50 first year students began with orientation at Ipswich on Monday, January 18 with classes officially commencing yesterday, January 20. A further 65 senior medical students start work at Ipswich Hospital next week...

Patient Societies From Armenia, Austria, Bulgaria, Hungary And Singapore Recognized For Their Innovative Projects

While awareness of osteoporosis among the public and health professionals is growing, there is still work to be done to ensure that doctors and other health professionals are adequately prepared to advise patients on the best possible care for osteoporosis.

What Clinical Research Is All About

How can researchers prove to the government that a newly-discovered drug or device is safe and effective? This is where the clinical trial comes in. The clinical trial is a research study designed to determine if a new pharmaceutical or medical device is sufficiently safe and effective for ...
(613) 686-5745 Cerepotec Pharmalef

Medical Students Regularly Stuck By Needles, Often Fail To Report Injuries

Medical students are commonly stuck by needles - putting them at risk of contracting potentially dangerous blood-borne diseases - and many of them fail to report the injuries to hospital authorities, according to a Johns Hopkins study published in the December issue of the journal Academic Medicine...

U.S. Medical Schools, Teaching Hospitals Continue To Drive Local Economies

A new report released by the AAMC (Association of American Medical Colleges) reveals that its member medical schools and teaching hospitals had a combined economic impact of over $512 billion on their state economies and the nation overall in 2008. Prepared for the AAMC by the consulting firm Tripp Umbach, the report found that the 131 accredited U.S. medical schools and nearly 400 major teaching hospitals represented by the AAMC employed more than 1.

California Medical Association Seeks To Reinstate Residency Program For Primary Care

The California Medical Association has asked the federal government to restore funding for the Stanislaus Family Medicine Residency Program so it can continue to train much-needed primary care physicians in the San Joaquin Valley. The Centers for Medicare and Medicaid Services (CMS) has ceased funding the program for failing to meet certain federal criteria, but CMA believes the program is too important to shut down and is urging authorities to reconsider.

Over the past few years, CROs have received the lion's share of outsourced clinical research revenue.

CROs were first organized as outsourcing service companies that provided only clinical trial management. Today, many CROs have expanded their scope of services to provide comprehensive management of the complex drug trial processes for their client companies, as well as providing access to ...
(613) 686-5745 Cerepotec Pharmalef

Partnership To Launch Hematology Program In Peru

Following the success of a program established in Uganda last year, the American Society of Hematology (ASH) and Health Volunteers Overseas (HVO) have again partnered to launch a new hematology program together with the Peruvian Social Security Health System, Empresa De Seguros De Salud (EsSalud). The goal of this program is to improve the hematology training of clinicians, laboratory technicians, technologists, and students.

Medical Students To Be Offered Management Training, UK

Medical students are to be offered management training under a new scheme launched by The British Association of Medical Managers (BAMM). BAMMdot will train students who are interested in management careers and structures within the health service, through Begin To Lead - a junior spin-off from BAMM's acclaimed Fit To Lead training programme, which will be organised to fit around students' existing academic commitments.

British Medical Association Award Winning Medical Authors And Editors Congratulated By Elsevier

Elsevier is pleased to announce that eight of its professional and scholarly books were honored at the annual BMA Medical Book Competition ceremony in London. An additional 19 Elsevier books were highly commended and five received commendation. In total, 640 books were entered to the BMA's competition with 130 prizes awarded with 23 first prizes, 63 highly commended prizes and 44 commended prizes.

Clinqua Inc. has embraced the concept that cooperation with other aspiring companies is the key to unlocking success in the clinical and biopharmaceutical research industry.

Clinqua is a Contract Research Organization www.clinqua.com that is attempting to change the age old notions that plagued the Clinical and Biopharmaceutical Industry, where in the past it was believed that for a company to survive it had to exist in competition with all others.

(613) 686-5745 Cerepotec Pharmalef

Queensland University Of Technology Launches One-Of-A-Kind Medical Research Facility

Queensland University of Technology launched a new $10.7 million research and training facility at The Prince Charles Hospital in Brisbane that aims to lead Australia in orthopaedic, critical care and artificial organs research. The Medical Engineering and Research Facility was officially opened by State Health Minister, The Hon Stephen Robertson.

Government Study Endorses AMA Calls For Greater Investment In Medical Workforce Training, Australia

The Australian Medical Education Study report - What makes for success in medical education? - endorses calls by the AMA for greater investment in medical education and training to produce a medical workforce capable of meeting the future health needs of a growing and ageing population...

$13 Million Grant To Develop Vaccines For Emerging Infectious Diseases, Simulation Tools Used To Train Next Generation Of Scientific Researchers

University of Rhode Island Professor Annie De Groot has been awarded a $13 million grant from the National Institutes of Health to pioneer the development and application of an integrated gene-to-vaccine program targeting emerging infectious diseases. It is the second multi-million dollar NIH grant awarded to URI researchers in recent months, coming on the heels of an $18 million award to a pharmacy professor in May.

Pharmalef Inc. is starting collaboration in development of new oral delivery platform

Pharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.Moreover, oral delivery improves patient compliance, improves treatment, ...
(613) 686-5745 Cerepotec Pharmalef

ASTRO And ACR Announce Joint Radiation Oncology Practice Accreditation Program

The American Society for Therapeutic Radiology and Oncology and the American College of Radiology have announced a new partnership for radiation oncology practice accreditation that builds on the ACR's current successful program that has served as the industry standard for more than 20 years.

More NHS Training Places Confirmed, Wales

Health Minister Edwina Hart announced an increase in the number of healthcare training courses to be funded in the next academic year to help meet One Wales commitments including reducing waiting times and improving access to healthcare. The number of courses to be funded by the Welsh Assembly Government from September 2009 is based on recommendations - which have been accepted in full - from the NHS, staff and unions on future workforce requirements.

Personality Has An Impact On Medical School Success

With medical schools flooded with applications, three industrial-organizational psychologists have conducted a study to determine if giving personality tests to prospective students would enable admissions officers to better predict which applicants will be successful. "Our findings show that personality factors do have a predictive value as to the success rate of admitted medical students...

Clinproxy is on the leading edge of adaptive clinical trials.

Clinproxy, www.clinproxy.com believes that adaptive clinical trials can drastically reduce the cost, time and subject drug exposure of clinical development. Classical clinical trials are planned with extreme dutiful details but once initiated fails to acknowledge that changes often need to be ...
(613) 686-5745 Cerepotec Pharmalef

Association Of Academic Health Centers Calls For National Plan To Recruit, Retain Health Care Workers

The Association of Academic Health Centers on Thursday during a briefing said that the federal government needs to help develop a national plan to recruit and retain health care workers to meet increased demand as the U.S. population ages,

Stress High Among Future Surgeons, Survey Reveals

The majority of general surgery residents in the United States say they are satisfied with their training and confident of their ability to perform, but a significant number feel that the hours and stress are straining their family life, and many express worries about future income and career prospects. The study by the Yale School of Medicine and the Yale School of Public Health appears in this week's Journal of the American Medical Association.

Agreement To Raise Indigenous Doctor Numbers And Improve Indigenous Health, Australia And New Zealand

There is an urgent need for more Indigenous doctors in Australia to help improve life expectancy and reduce infant mortality rates of Aboriginal and Torres Strait Islander peoples, a need that will tomorrow (Saturday 4 October) see http://www.medicaldeans.org.au/ and the Australian Indigenous Doctors' Association (AIDA) sign a collaborative agreement.

The World Is Getting Better!

According to Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization, the world is getting better, no matter what critics say. Today’s life expectancy is the highest in human history. In Western countries, we ...
(613) 686-5745 Cerepotec Pharmalef

New Medical Defence Union Journal For Foundation Year Doctors, UK

Ward Round, a brand new journal for foundation year doctors, has been launched by the Medical Defence Union (MDU), the UK's leading medical defence organisation. Ward Round, will be published twice-yearly and sent to the MDU's F1 and F2 members. The first issue* focuses on what F1 and F2 doctors need to know about patient capacity and the Mental Capacity Act 2005. MDU solicitor, Ian Barker, looks at a number of scenarios and explains how the law will work in practice.

New Mexico, Other States Implementing Legislation To Ensure Culturally Competent Care

New Mexico is among a "handful of states that are legislating culturally competent care" to ensure that health care providers receive appropriate training, the AP/Las Cruces Sun-News reports. According to the AP/Sun-News, the way a physician enters a room and greets and communicates with patients can be viewed differently by different cultures.

Study Details Strategy For Boosting Ranks Of Black HIV/AIDS Researchers

African Americans, who make up 13 percent of the U.S. population, are disproportionately affected by AIDS, accounting for nearly 49 percent of newly diagnosed HIV/AIDS cases nationwide. About 500,000 African Americans are now living with HIV/AIDS. Yet there are very few African American HIV/AIDS researchers, due to historical, social and other factors that prevent them from training in the biomedical, behavioral and social aspects of HIV/AIDS research.

Pharmaceutical companies are relying on outsourcing strategies

It is imperative that pharmaceutical and biotechnology companies pass their product through the testing and regulatory process in a rapid, cost-effective manner. To accomplish this goal, pharmaceutical companies are relying on outsourcing strategies to provide the services that can ...
(613) 686-5745 Cerepotec Pharmalef

Indiana University School Of Medicine To Advance 'More Doctors For Indiana' Plan With State Legislators

The Indiana University School of Medicine Regional Medical Education campus directors, faculty and medical students from across the state will gather at the Statehouse from 10 a.m. to 2 p.m., Tuesday, Feb. 24, to bring the school's message of "more doctors for Indiana" to members of the Indiana General Assembly.

Scenarios To Test Health Students' Skills - University Of Wolverhamton, UK

Health students will be put to the test in a series of real-life scenarios as part of a special week of activities at the University of Wolverhampton. The University's simulation wards, Pharmacy department and a mock flat will be used at the School of Health and School of Applied Sciences to enable students from a variety of different backgrounds to practice their skills on actors in scenarios they could face when they qualify.

ASGE Recognizes 32 Endoscopy Units For Quality And Safety

The American Society for Gastrointestinal Endoscopy (ASGE) has recognized 32 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States...

CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published

September 18, 2008A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: ...
(613) 686-5745 Cerepotec Pharmalef

Health And Social Care Expected To Boost Apprenticeship Awards Entries, UK

The search is on to find the nation's top Apprenticeship employers as the Learning and Skills Council (LSC) launches its prestigious sixth annual Apprenticeship Awards. Employers of all sizes and from all sectors including health and social care are encouraged to enter.

RCN Welcomes NMC Consultation On Pre-registration Training, UK

The Royal College of Nursing (RCN) welcomed the start of a consultation period announced by the Nursing and Midwifery Council (NMC) on standards for the development of programmes that will prepare students to become registered nurses...

Former Police Officer Awarded Australian Medical Association Indigenous Medical Scholarship

A former police officer and industrial paramedic who wants to help improve the health of Aboriginal people has won the AMA Indigenous Peoples' Medical Scholarship for 2009. Terry Morich, who celebrated his 44th birthday today, was awarded the scholarship by AMA Federal President, Dr Rosanna Capolingua. Valued at $9,000 for each year of study, the scholarship provides support for Aboriginal and Torres Strait Islander students studying medicine.

Clinproxy is on the leading edge of adaptive clinical trials.

Clinproxy, www.clinproxy.com believes that adaptive clinical trials can drastically reduce the cost, time and subject drug exposure of clinical development. Classical clinical trials are planned with extreme dutiful details but once initiated fails to acknowledge that changes often need to be ...
(613) 686-5745 Cerepotec Pharmalef

$50 Million 'Penn Integrates Knowledge' Neurosciences Initiative Announced By Penn

The University of Pennsylvania will make a major investment in neuroscience, the interdisciplinary study of brain/behavior relationships and nervous-system diseases, with a $50 million contribution from Penn's Health System to endow five new Penn Integrates Knowledge (PIK) professorships.

Doctors Face Image Problems; Patients Deal With Shortages, Are Urged To Question Care

Doctors must not only face the fading image of primary care providers, but also physician shortage issues. Meanwhile, some experts suggest patients consider saying "no" to their doctor to control health care costs.

More Training, Improved Tools Needed For African Health Workers Performing Male Circumcisions, Study Finds

African health workers performing male circumcision in an effort to curb the spread of HIV need better tools and more training to avoid high rates of complications, according to a World Health Organization study published Monday in the WHO Bulletin, Reuters Health reports.

It is recommended that sponsor companies should first check what budget they can allocate, and then seek Clinqua Inc. expertise in achieving their goal.

It is an undesirable reality, but the development of pharmaceutical drugs is a costly undertaking. Yet, these costs are necessitated by the substantial investment of both time and resources of the companies in question. It stands to reason that if a company is willing to invest millions of ...
(613) 686-5745 Cerepotec Pharmalef

ASH To Encourage High School Students To Pursue Biomedical Research Through Special Symposium And Science Curriculum

The American Society of Hematology (ASH) will host its annual High School Student Symposium at the New Orleans Marriott on Thursday, December 3, at 8:00 a.m. CST. The symposium, which encourages an interest in hematology, the biological sciences, and medical research, is held in conjunction with the Society's 51st Annual Meeting...

Biomet And OREF Collaborate To Sponsor Orthopaedic Graduate Medical Education Programs

Biomet, Inc. and the Orthopaedic Research and Education Foundation (OREF) announced today a new partnership to provide multi-year funding to support graduate medical education programs in orthopaedic surgery. Effective immediately, Biomet will provide expanded funding for orthopaedic fellowship and resident education programs in partnership with OREF.

Strange Bedfellows: Science and Poetry, University of Montreal

Science and poetry may not seem like a natural match. But there was a time when scientific poetry was a literary genre that allowed readers to learn about science. Professor Michel Pierssens of the Université de Montréal Department of French Literature wants to shed light on this forgotten genre dating back to the first century BC.

Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.

Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of ...
(613) 686-5745 Cerepotec Pharmalef

Congress Launches The First National Research Program Focused On Technology And Learning

Congress has authorized a major new research center, the National Center for Research in Advanced Information and Digital Technologies, that will bring the same focused, sustained research funding to technology and learning that the federal government has funded for years in technology for health care at the National Institutes of Health and technology for energy at the Department of Energy.

1994 Group Welcomes CBI's Higher Education Funding Proposals But Warns Of 'Valley Of Death' Ahead For University Finances

The 1994 Group welcomes the CBI report published yesterday (Monday) which backs the 1994 Group's proposals (set out in a speech on the 23rd June) to maintain the quality of the UK's universities through enhanced funding. The CBI's report recommends that student loans should be provided at the government's cost of borrowing and highlights the necessity of an increase in tuition fees to maintain quality.

A Selection Of Editorials And Opinions

A Lifeline For Primary Care The New England Journal of Medicine Primary care in the United States needs a lifeline. In 2009, for the 12th straight year, the number of graduating U.S. medical students choosing primary care residencies reached dismally low levels (Bodenheimer, Grumbach and Berenson, 6/25).

Patients enrolment is a greatest challenge for the clinical research industry in the USA, Canada and European Union.

The efficiency of a clinical trial can be greatly compromised by the challenge of efficiently enrolling patients, securing clinical trial sites, and collecting data. Pressure to expedite clinical trials, while reducing the cost of the trials, has led to yet another new, rapidly evolving ...
(613) 686-5745 Cerepotec Pharmalef

AAMC Urges Congress To Stimulate The Economy Through Increased Support For NIH And Medical Education

The AAMC (Association of American Medical Colleges) called on Congress today to consider the role U.S. medical schools and teaching hospitals play in the nation's fiscal health as lawmakers develop legislation to stimulate economic recovery. In a recent letter to congressional leaders, the AAMC notes that medical schools and teaching hospitals have a substantial economic and social impact within the counties and cities they serve.

Bayer USA Foundation Awards $279,000 Grant To Exemplary STEM Education Diversity Program

Reaffirming its longstanding commitment to help strengthen science, technology, engineering and mathematics (STEM) education and bring more women and minorities into STEM fields, the Bayer USA Foundation today awarded a $279,000 grant over three years to the nationally lauded Mathematics, Engineering, Science Achievement (MESA) program to help educationally disadvantaged students in the San Francisco Bay area to achieve and succeed in these subjects.

The Royal Society For Public Health Announces It Will Be Delivering Training Sessions

The Royal Society for Public Health (RSPH) announces it will be delivering training sessions for the RSPH Level 1 Health Awareness and the RSPH Level 2 Understanding Health Improvement awards. Are your colleagues feeling tired and unmotivated? Is your work environment getting you down? Do you want to find out how you might make a difference to the health of friends, colleagues and those in your community? Well, good news: healthcare is changing.

Limdato’s Grasp On Streamlining Clinical Trials

Limdato, www.limdato.com understands that executing a successful clinical trial requires a seamless coordination and communication with all individuals involved on levels on the trial. On average clinical trials in Phases 1,2,3 go beyond deadlines by 30%. These delays cost the ...
(613) 686-5745 Cerepotec Pharmalef

AAMC Comments On Macy Medical Education Report

AAMC (Association of American Medical Colleges) President and CEO Darrell G. Kirch, M.D., issued the following statement today on the Josiah Macy Jr. Foundation's new report, "Revisiting the Medical School Mission at a Time of Expansion": "Representatives of the AAMC were pleased to be a part of the important dialogue that resulted in this new report on medical schools in the 21st century.

British Medical Association Criticises Cuts To Student Grants

Medical student leaders today (Wednesday, 29th October 2008) attacked the government's decision to cut financial support to thousands of students in England from next year. The changes announced today in a written parliamentary answer by the Universities Secretary John Denham, will see reductions in the number of students who will be able to receive annual financial grants.

Health Care And Nursing Jobs Continue To Be In Demand

The new year promises new health care industry jobs around the country, but in some places, such as Indiana, a shortage of nursing instructors could lead to fewer trained nurses to fill those jobs...

Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).

Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a ...
(613) 686-5745 Cerepotec Pharmalef

Study Analyzes The Lack Of Internal Medicine Specialists

Due to patient complexity, the practice environment, and the lifestyle, medical students are becoming increasingly less likely to choose internal medicine as a career specialty. These findings are published in the medical education-themed September 10 issue of JAMA. Much of the chronic care for older and medically complex patients is provided by internists in primary care and subspecialty practice.

University Of Central Florida Med Students Volunteer To Help Sick Kids, Families In Community On Saturday

Twenty medical students from the University of Central Florida College of Medicine will cook and serve meals to families of ill children Saturday, Nov. 7, at the Ronald McDonald House on the campus of Arnold Palmer Medical Center. It will be the first official community service event for the 41-member charter class, which began classes in August.


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .<br />In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture. <br /><br />One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound. <br />The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material. <br /><br />Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV. <br /><br />This step can be repeated in the future in order to produce more of compound III. <br />Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.<br /><br />Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment. <br /><br />At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.<br />Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.<br /><br />In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.<br />US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. <br /><br />This company is also developing a family of other promising novel chemical compounds. <br /><br />Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans. <br />Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.<br /><br />Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.<br />Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.<br /><br />Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.<br /><br />Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer. <br /><br />Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union. <br />Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.<br /><br />In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.<br />Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market. <br /><br />Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations. <br />Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.<br /><br />They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities. <br /><br />They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.<br />CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008<br /><br />A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838<br /><br />1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.<br /><br />2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.<br /><br />3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.<br /><br />4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.<br /><br />5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.<br /><br />6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.<br /><br />7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.<br /><br />9. The method according to claim 8, wherein said head trauma injury is closed head injury.<br /><br />10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.<br /><br />11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.<br /><br />12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.<br /><br />13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.<br /><br />14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.<br /><br />15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.<br /><br />16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.<br /><br />17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.<br /><br />18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.<br /><br />19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.<br /><br />21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.


Viev all previous articles...

Some Article Feeds provided by MedicalNewsToday.com

More Articles of interest...

Adult Stem Cell Injections May Reduce Pain And Improve Walking In Severe Angina Patients

Preliminary data presented on March 28 as a late-breaking abstract at the American College of Cardiology's 58th annual scientific session from the largest CD34+ adult stem cell study for heart disease has shown the first evidence that delivering a potent form of autologous (from the patient) adult stem cells into the heart muscle of patients with severe angina may result in less pain and improved exercise tolerance.

Although Hepatitis C Treatment Reduces The Virus, Liver Damage Continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and are reported in the Dec. 4 issue of the New England Journal of Medicine.

Roche And InterMune Initiate Phase 2b Clinical Trial Of R7227/ ITMN-191 In Patients With Chronic Hepatitis C

Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, R7227/ ITMN-191, in combination with PEGASYS® (pegylated interferon alfa- 2a) and COPEGUS® (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of R7227/ ITMN-191, for a treatment duration of up to 24 weeks.

US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril Derivatives

Cereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. This company is also developing a family of other promising novel chemical compounds. Proof of efficacy of these compounds has been obtained in ...
(613) 686-5745 Cerepotec Pharmalef

The Multiple Myeloma Research Consortium Announces Initiation Of First Four-Drug Combination Study To Treat Newly Diagnosed Multiple Myeloma Patients

The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a four-drug combination study with REVLIMID® (lenalidomide), VELCADE® (bortezomib) for Injection, DOXIL® (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.

Window For Effective Stroke Treatment Expanded

Once symptoms start, there's only a tiny window of time for stroke victims to get life-saving treatment. Now, research from the Stanford University School of Medicine has cracked that window open a bit wider. If a patient arrives at the emergency room within three hours of experiencing stroke symptoms, doctors can administer a potent clot-busting medication and often save critical brain tissue.

Emisphere Technologies Announces The Launch Of A Human Clinical Trial For Oral Parathyroid Hormone (PTH)

Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R) technology, for the treatment of postmenopausal osteoporosis.

Pharmalef Inc. is starting collaboration in development of new oral delivery platform

Pharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.Moreover, oral delivery improves patient compliance, improves treatment, ...
(613) 686-5745 Cerepotec Pharmalef

Enzon Opens A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection)...

Ore Pharmaceuticals Announces Completion Of Multiple Ascending Dose GL1001 Clinical Phase 1 Trial

Ore Pharmaceuticals Inc. (NASDAQ: ORXE) today announced that it has completed dosing volunteer subjects in its multiple ascending dose clinical study of the Company's lead drug candidate, GL1001. The study, initiated in September, was a blinded, placebo-controlled study in 32 healthy volunteers which studied multiple ascending doses up through the highest planned dose of 1800mg. The compound was orally administered once daily for 14 days.

News From The Journal Of The National Cancer Institute, August 26 2008

Novel Trial Design Aims to Speed Drug Development Researchers propose a novel multi-arm trial design that can test several therapies simultaneously and could speed drug development in cancer. Scientists have gained important insights into the biological underpinnings of cancer, but this knowledge has not led to a jump in the number of therapies approved for clinical use.

Use of the Cereprotex prior to and after the CABG procedures to substantially reduce or eliminate the effects of neuro-impairment.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in ...
(613) 686-5745 Cerepotec Pharmalef

Can Light Make Your Toenails Look Better? Keraderm Has Clinical Trials Underway To Find Out

Is it possible to use the healing power of light to treat infections? Keraderm, a leader in the development of light-based treatments for infections, thinks so. Keraderm announced full enrollment for pivotal trials to obtain FDA clearance of its phototherapy treatment for onychomycosis (fungal nail infections). The objectives of the pivotal trials are to confirm the efficacy and safety of Keraderm's treatment for patients with onychomycosis.

Researchers Pinpoint Best Time To Begin Toilet Training For Children

Researchers at The Bristol-Myers Squibb Children's Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and UMDNJ-Robert Wood Johnson Medical School (UMDNJ-RWJMS) have completed a study that pinpoints the period between 24 and 32 months of age as most effective time frame for parents to begin toilet training lessons with their children...

European Medicines Agency's COMP Adopts Positive Opinion For The Orphan Drug Designation For Protalix's Taliglucerase Alfa

Protalix BioTherapeutics, Inc...

Clinproxy believes in the concept that cooperation with other CROs is the key to unlocking great accomplishments in the biopharmaceutical research industry.

Clinproxy is a Contract Research Organization www.clinproxy.com that is attempting to change the idea that has overwhelmed the Biopharmaceutical Industry, that for a company to survive it had to exist in competition with all others.Clinproxy, on the other hand has embraced the ...
(613) 686-5745 Cerepotec Pharmalef


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .<br />In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture. <br /><br />One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound. <br />The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material. <br /><br />Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV. <br /><br />This step can be repeated in the future in order to produce more of compound III. <br />Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.<br /><br />Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment. <br /><br />At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.<br />Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.<br /><br />In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.<br />US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. <br /><br />This company is also developing a family of other promising novel chemical compounds. <br /><br />Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans. <br />Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.<br /><br />Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.<br />Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.<br /><br />Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.<br /><br />Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer. <br /><br />Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union. <br />Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.<br /><br />In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.<br />Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market. <br /><br />Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations. <br />Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.<br /><br />They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities. <br /><br />They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.<br />CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008<br /><br />A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838<br /><br />1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.<br /><br />2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.<br /><br />3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.<br /><br />4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.<br /><br />5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.<br /><br />6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.<br /><br />7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.<br /><br />9. The method according to claim 8, wherein said head trauma injury is closed head injury.<br /><br />10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.<br /><br />11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.<br /><br />12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.<br /><br />13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.<br /><br />14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.<br /><br />15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.<br /><br />16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.<br /><br />17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.<br /><br />18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.<br /><br />19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.<br /><br />21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
HOME . ARTICLESMORE FEATURES .  CONTACT

613-686-5745 Clinical training is not a Scam, you should take training courses that are not a scam. Not a clinical trial scam for training in the clinical trail industry. Clinical Research Associate Courses maybe not a scam but not really a scam you learn alot about Clinic trials. Don't tell me its a scam as I think it does not work. Opinions of Clinical Training seem to say these courses are a scam. This is not truly a scam, scams are not good and clinical trails is not one of them. Take Clinical courses and you won't be scammed. Is Clinical Research Associates Training a scam? 613-686-5745

And a pair of them on 800notes.com. pharmaceutical company you hope to one day work for. Similar to comments bearing the same signature and left elsewhere, it includes talk of defamation, and “offensive or harassing content” removing this blog trinity includes a recruiting agency, a pharma company, and a school

INSTITUTIONS THAT OFFERS A PRACTICAL ORIENTED COURSE IN CLINICAL RESEARCH.ClinfoSource online GCP training courses WARN OF ONE INSTITUTE. STAY AWAY. they will help you find a job in India. certificates courses, numerous spelling and grammar mistakes. Looking for clinical research staff nation-wide to prepare and initiate clinical trials. report a fraud. report this scam. moving forward in their clinical trial as it was approved.Espoir and PharmAlef are a complete and utter fraud

qualified for any clinical trials-related positions, but we highly recommend you get a clinical trials certificate. QA experience: GMP, GLP and GCP certificate through the training and certification  programs accredited by the International Biopharmaceutical Association. Certificate form Kriger and Bachelor's degree in science and clinical research experience preferred. I am still interested in pursuing a career in clinical research. 613-686-5745

http://www.clinicaltoday.com/ . http://pharmaindustrytoday.com/ . http://www.medicaltrainingtoday.com/ . http://medicalnewspress.com . http://medicaldevicesnews.com . http://MedConferencestoday.com . http://regulatoryaffairstoday.com